Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Schett

Showing results (581-590 of 1,050) with videos related to

Pageof 105
Sort By:
Clinical and Experimental Rheumatology|July 12, 2021
Virtual teaching for medical students during SARS-CoV-2 pandemicAlexander Pfeil, Marcus Franz, Tobias Hoffmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 16, 2009
The alpha-isoform of p38 MAPK specifically regulates arthritic bone lossChristina Böhm, Silvia Hayer, Anita Kilian, et al.
Annals of the Rheumatic Diseases|November 14, 2012
Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signallingAlfiya Distler, Lisa Deloch, Jingang Huang, et al.
Annals of the Rheumatic Diseases|January 22, 2014
Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerabilityAlfiya Distler, Veronika Lang, Tina Del Vecchio, et al.
Clinical Rheumatology|November 5, 2021
Correction to: Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52Frank Behrens, Soyi Liu Leage, Christophe Sapin, et al.
Clinical Rheumatology|September 13, 2021
Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52Frank Behrens, Soyi Liu Leage, Christophe Sapin, et al.
Arthritis Research & Therapy|July 5, 2019
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patientsDavid Simon, Arnd Kleyer, Sara Bayat, et al.
Nutrients|October 9, 2019
The Role of Dietary Fiber in Rheumatoid Arthritis Patients: A Feasibility StudyJulian Häger, Holger Bang, Melanie Hagen, et al.
JAMA|March 5, 2004
Soluble RANKL and risk of nontraumatic fractureGeorg Schett, Stefan Kiechl, Kurt Redlich, et al.
Annals of the Rheumatic Diseases|May 24, 2013
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosisClara Dees, Inga Schlottmann, Robin Funke, et al.
Pageof 105

Showing results (581-590 of 1,050) with videos related to

Sort By:
Pageof 105
Clinical and Experimental Rheumatology|July 12, 2021
Virtual teaching for medical students during SARS-CoV-2 pandemicAlexander Pfeil, Marcus Franz, Tobias Hoffmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 16, 2009
The alpha-isoform of p38 MAPK specifically regulates arthritic bone lossChristina Böhm, Silvia Hayer, Anita Kilian, et al.
Annals of the Rheumatic Diseases|November 14, 2012
Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signallingAlfiya Distler, Lisa Deloch, Jingang Huang, et al.
Annals of the Rheumatic Diseases|January 22, 2014
Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerabilityAlfiya Distler, Veronika Lang, Tina Del Vecchio, et al.
Clinical Rheumatology|November 5, 2021
Correction to: Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52Frank Behrens, Soyi Liu Leage, Christophe Sapin, et al.
Clinical Rheumatology|September 13, 2021
Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52Frank Behrens, Soyi Liu Leage, Christophe Sapin, et al.
Arthritis Research & Therapy|July 5, 2019
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patientsDavid Simon, Arnd Kleyer, Sara Bayat, et al.
Nutrients|October 9, 2019
The Role of Dietary Fiber in Rheumatoid Arthritis Patients: A Feasibility StudyJulian Häger, Holger Bang, Melanie Hagen, et al.
JAMA|March 5, 2004
Soluble RANKL and risk of nontraumatic fractureGeorg Schett, Stefan Kiechl, Kurt Redlich, et al.
Annals of the Rheumatic Diseases|May 24, 2013
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosisClara Dees, Inga Schlottmann, Robin Funke, et al.
Pageof 105